Stable solid pharmaceutical dosage form comprising crystalline form of her2 / mutegfr inhibitor and process for its preparation

Abstract

The present invention relates: ● to a tablet formulation comprising crystalline Hydrate 1 Modification A form of the compound 3-(3-chloro-2-methoxy-anilino)-2-[3-[[(2S)-1,4-dioxan-2-yl]methoxy]-4-pyridyl]-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine-4-one, of formula (A): , ● wherein the content of water is greater than 0% (w / w), particularly greater than 0% and less than or equal to 4%, of the total weight of said compound of formula (A); ● to methods of preparing said tablet formulation, and ● to uses of said tablet formulation in the prophylaxis and / or treatment of diseases.